Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk
SYDNEY, AU, Mar 25, 2019 - (ACN Newswire) - Clinical Network Services (CNS) USA, an integrated services group focused on clinical product development and subsidiary of Asia-Pacific specialist CRO Novotech, today announced the appointment of Dr Robert Malone as Principal Consultant in its Washington D.C. office. CNS is headquartered in Australia with offices in New Zealand, the UK and the USA.
 | Dr Robert Malone, Principal Consultant at the CNS BioDesk, Washington D.C. |
Dr Malone brings more than 20 years of management and leadership experience in academia, pharmaceuticals and biotechnology, with deep expertise in regulatory and medical strategy for global clinical product development. Dr Malone is an internationally recognised physician and scientist for his work in clinical trials in the areas of vaccines, gene therapy, biodefense and immunology, and specifically as one of the original inventors of DNA vaccination and multiple non-viral gene therapy technologies (RNA and DNA).
Commenting on the new role, Robert said: "I am delighted to join the CNS BioDesk USA consulting team; this is an exciting opportunity to work within a highly professional and experienced group that is dedicated to adding value to clients' early phase programs and their US regulatory strategies."
Russell Neal, CNS Managing Director said: "Dr Malone brings a wealth of industry and consulting experience to our US BioDesk team, and his appointment reflects CNS' ongoing commitment to the continuous growth and evolution of BioDesk to service CNS' international clients as they navigate US and global regulatory strategies."
CNS' BioDesk division is an intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval. It is a uniquely internationally experienced team with particular expertise in the areas of vaccines, oncology, infectious disease as well as cell and gene therapies.
CNS and Novotech, the largest Asia-Pacific-based CRO, merged in late 2018 as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials.
About Clinical Network Services Clinical Network Services (CNS) is an integrated services group focused on product development based in Australia with offices in New Zealand, the UK and the USA, which creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials and the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with a committed, highly experienced Australian/New Zealand clinical services and biometrics team. More about CNS and its intelligent development services at www.clinical.net.au
About BioDesk CNS' BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. More about BioDesk services can be found at www.cnsbiodesk.com
About Novotech - https://novotech-cro.com/welcome Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. For more, see www.novotech-cro.com.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0
Media Contact: communications@novotech-cro.com Susan Fitzpatrick-Napier, AU: +61 2 8218 2144 USA: +1 415 951 3228, Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd Sectors: Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Team Mitsubishi Ralliart Conducts Shakedown Ahead of Asia Cross Country Rally 2025: Targeting First Overall Championship in Three Years Aug 07, 2025 18:40 JST
|  Toyota to Establish New Vehicle Manufacturing Plant in Japan Aug 07, 2025 18:31 JST
|  MHI Heat Pumps NZ Wins People's Choice Award for Third Year Running Aug 07, 2025 17:32 JST
|  FWD Group completes build-out of high-net-worth hub in Asia Aug 07, 2025 14:00 JST
|  Shoucheng Highlights VC Role and Robot Lineup at WRC 2025 Aug 07, 2025 10:50 JST
|  Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept Aug 06, 2025 19:40 JST
|  Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India Aug 06, 2025 18:54 JST
|  Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management Aug 06, 2025 11:00 JST
|  MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates Aug 05, 2025 22:02 JST
|  12 New Companies Join Toyota Woven City as Inventors Aug 04, 2025 21:09 JST
|  Honda HRC Wins 46th Suzuka 8 Hours Endurance Road Race Aug 04, 2025 20:43 JST
|  MUFG Bank and Fujitsu collaborate on preventive health ecosystem to address societal challenges Aug 04, 2025 11:00 JST
|  Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi" Aug 01, 2025 19:00 JST
|  Mitsubishi Motors and Security Bank launch Mitsubishi Motors Finance Philippines Inc. Aug 01, 2025 17:00 JST
|  Honda Turkiye A.S. decided to establish Motorcycle Production Factory Aug 01, 2025 16:45 JST
|  Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells Aug 01, 2025 11:20 JST
|  Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle Aug 01, 2025 11:00 JST
|  Fujitsu starts official development of plus-10,000 qubit superconducting quantum computer targeting completion in 2030 Aug 01, 2025 10:20 JST
|  Revenue of LEQEMBI(R) (Preliminary Basis) Jul 31, 2025 18:27 JST
|  Transfer of Sharp Mie Plant No.2 and part of the land at Mie Base Jul 31, 2025 17:11 JST
|
More Latest Release >>
|